Ventricular Dysfunction

Subscribe to Selected New Research on Ventricular Dysfunction

583 relevant articles (28 outcomes, 55 trials/studies) found for this Disease

Description: A condition in which HEART VENTRICLES exhibit impaired function.

Also Known As:

Dysfunction, Ventricular; Dysfunctions, Ventricular; Ventricular Dysfunctions

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 18525

Heart Diseases: 12357

Ventricular Dysfunction: 583

Left Ventricular Dysfunction: 2588

Right Ventricular Dysfunction: 240

Related Diseases

1.	Heart Failure
2.	Coronary Artery Disease (Coronary Atherosclerosis)
3.	Cardiac Arrhythmias (Arrythmia)
4.	Tachycardia (Tachyarrhythmias)
5.	Ventricular Tachycardia

Experts

1.	Rossoni, Giuseppe: 3 articles (04/2008 - 11/2003)
2.	Manfredi, Barbara: 2 articles (02/2007 - 11/2003)
3.	Berti, Ferruccio: 2 articles (02/2007 - 11/2003)
4.	Collard, Charles D: 1 article (08/2008)
5.	Fox, Amanda A: 1 article (08/2008)
6.	Shernan, Stanton K: 1 article (08/2008)
7.	Liu, Kuang-Yu: 1 article (08/2008)
8.	Jarolim, Petr: 1 article (08/2008)
9.	Body, Simon C: 1 article (08/2008)
10.	DeSantis, Stacia M: 1 article (08/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ventricular Dysfunction:

1.	Cardiac GlycosidesIBA 01/01/1999 - "Despite the documented efficacy of cardiac glycosides in improving symptoms in patients with heart failure caused by systolic ventricular dysfunction, considerable debate continues as to whether the use of this class of drugs should continue into the next millennium" 10/01/1993 - "Although supported by 2 centuries of anecdotal clinical evidence, the safety and efficacy of the cardiac glycosides for the treatment of congestive heart failure due to systolic ventricular dysfunction had never been rigorously examined by prospective clinical trials until the past decade" 03/09/1999 - "Moreover, despite the fact that the molecular target for the cardiac glycosides, the alpha-subunit of sarcolemmal Na+K+-ATPase (or sodium pump) found on most eukaryotic cell membranes, has been known for several decades, it remains controversial whether the sympatholytic or positive inotropic effects of these agents is the mechanism most relevant to relief of heart failure symptoms in humans with systolic ventricular dysfunction" Order ALL the reference details at left...
2.	Milrinone (Primacor)FDA LinkGeneric 09/01/1994 - "BACKGROUND: Milrinone is a phosphodiesterase inhibitor with positive inotropic and vasodilator effects that are useful in the treatment of ventricular dysfunction after cardiac surgery" 04/01/1998 - "Amrinone and milrinone are phosphodiesterase inhibitors with positive inotropic effects useful for the treatment of ventricular dysfunction after cardiac surgery" Order ALL the reference details at left...
3.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 03/01/2004 - "The ongoing large controlled, double blind, randomized trials will provide an important information concerning the efficacy of ACE inhibitors to prevent progression of ventricular dysfunction in paediatric oncologic patients." 01/01/2003 - "DESIGN AND METHODS: Description of adverse events in reports of randomised clinical trials of ACE inhibitors in CHF or ventricular dysfunction was examined, and a meta-analysis was performed" 05/01/1994 - "The role and use of ACE inhibitors in patients with chronic systolic ventricular dysfunction, established in earlier trials, has been further clarified" 06/01/2002 - "The prescription of angiotensin converting enzyme inhibitors prescription to patients with ventricular dysfunction increased with the severity of ventricular dysfunction and was more frequent in patients admitted to the cardiology department" 01/01/2001 - "ACE inhibitors improve function and survival in adults with CHF, and they probably do the same in children with systemic ventricular dysfunction" Order ALL the reference details at left...
4.	Brain Natriuretic Peptide (Natrecor)FDA Link 03/01/2006 - "Plasma brain natriuretic peptide (BNP) levels have a high predictive value for excluding patients with ventricular dysfunction and therefore could serve as a marker for identifying patients who demonstrate improved LV function" 01/01/2000 - "The purpose of this study was to evaluate the significance of brain natriuretic peptide (BNP) in the diagnosis of HF with systolic or isolated diastolic ventricular dysfunction" 08/01/2008 - "RESULTS: Preoperative plasma B-type natriuretic peptide concentration predicted ventricular dysfunction, hospital stay, and mortality in univariate and multivariable analyses" 08/01/2008 - "Multivariable analyses assessed independent roles of preoperative B-type natriuretic peptide in predicting postoperative ventricular dysfunction, hospital stay, and 5-year all-cause mortality" 07/04/2008 - "In adults, plasma brain natriuretic peptide (BNP) level has been shown to reflect systemic ventricular dysfunction" Order ALL the reference details at left...
5.	TNFR-Fc fusion protein (etanercept)FDA Link 05/01/2007 - "In animal models and small-scale clinical trials, anti-TNF therapy showed some promise in treating chronic heart failure, whereas larger, multicenter, randomized, placebo-controlled clinical trials (i.e., RECOVER [Research into Etanercept Cytokine Antagonism in Ventricular Dysfunction] and RENAISSANCE [Randomized Etanercept North American Strategy to Study Antagonism of Cytokines]) failed to show a statistically significant difference in composite clinical function score for anti-TNF therapy versus placebo" 08/01/2008 - "METHODS AND RESULTS: We measured baseline blood serum collagen (amino-terminal propeptide of collagen III [PIIINP], metalloproteinase 1 [MMP-1], tissue inhibitor of metalloproteinase 1 [TIMP-1]), and inflammatory (high-sensitivity C-reactive protein [(hsCRP], interleukin [IL]-18, IL-10) markers in 1009 patients enrolled in the Research into Etanercept Cytokine Antagonism in Ventricular Dysfunction (RECOVER) trial" Order ALL the reference details at left...
6.	OxygenIBA 05/01/2005 - "These data provide further evidence that primary asynchrony is not only a marker of chronic ischemic ventricular dysfunction, but is associated with a modified contraction pattern in which normal oxygen tension coexists with reduced perfusion." 12/21/2004 - "BACKGROUND: Oxygen deprivation for prolonged periods of time provokes cardiac cell death and ventricular dysfunction" 01/01/2000 - "Oxygen deprivation for prolonged periods leads to cardiac cell death and ventricular dysfunction" 03/01/1993 - "Although oxygen free radical production is thought to occur only early during postischemic reflow, the use of oxygen radical scavengers in a model of regional stunning was shown to attenuate the ventricular dysfunction." 10/01/1983 - "When guidelines for patient selection and dosing are adhered to, ventricular dysfunction and cardiac decompensation secondary to atherosclerotic occlusive coronary artery disease can be improved without adversely affecting the myocardial oxygen supply and demand balance" Order ALL the reference details at left...
7.	Anti-Arrhythmia AgentsIBA 04/01/1998 - "INTRODUCTION: The interaction between acute ventricular dilatation (AVD) as one aspect of ventricular dysfunction and Class I and III antiarrhythmic drugs is uncertain" 10/23/1997 - "These developments may be summarized as follows: (1) it has become clear that arrhythmias merit treatment only for the relief of symptoms, with improved quality of life, and for prolongation of survival by reducing arrhythmic deaths; (2) suppression of arrhythmias--symptomatic or asymptomatic--may not necessarily decrease mortality, the net impact on mortality being agent-specific; (3) antiarrhythmic drugs have the propensity to decrease as well as to increase cardiac arrhythmias (producing proarrhythmias); (4) the most important determinant of arrhythmia mortality is the degree and nature of ventricular dysfunction; and (5) only controlled trials have the potential to establish the effect of treatment on mortality in patients with cardiac arrhythmias" 05/01/1993 - "AV valve incompetence during SVT was always associated with extremely severe hydrops and seemed to indicate the most severe degree of ventricular dysfunction, which could influence the selection of antiarrhythmic drugs" 03/12/1998 - "Before initiating drug therapy, the presence or absence of structural heart disease must be determined, because in the absence of structural heart disease, antiarrhythmic drugs generally can be given rather safely, but in the presence of structural heart disease, especially when associated with ventricular dysfunction, there is an important risk of developing ventricular proarrhythmia" 03/01/1997 - "In young children with incessant ventricular tachycardia and severe ventricular dysfunction, the management of tachycardia with conventional antiarrhythmic drugs remains a major therapeutic challenge because most of these drugs can further depress myocardial function" Order ALL the reference details at left...
8.	glucuronyl glucosamine glycan sulfate (Vessel)IBA 12/01/2002 - "CONCLUSIONS: We found that in clinically selected patients with severe ventricular dysfunction, CABG compared with percutaneous revascularization achieves more complete revascularization, improved LV function, fewer cardiac events, and fewer target vessel revascularizations, but does not affect mid-term survival" 01/01/1993 - "From the results of the study one may conclude that, in patients with previous myocardial infraction exercise, ST-segment elevation is a consequence of sub-occlusion of the left anterior descending coronary artery with severe ventricular dysfunction either in patients with one or multiple vessel disease." 07/01/1998 - "Cardiac catheterization showed three vessel disease with ventricular dysfunction (EF 40%)" 05/24/1995 - "The corresponding attributable risk fractions were 1%, 22%, and 9% for single-vessel disease, multivessel disease, and ventricular dysfunction, respectively" 04/01/1984 - "All 24 patients had severe triple-vessel disease and moderate to marked ventricular dysfunction, with eight (33%) requiring intra-aortic balloon pump (IABP) support for profound cardiac decompensation preoperatively" Order ALL the reference details at left...
9.	Captopril (Capoten)FDA LinkGeneric 02/01/1993 - "This study indicates that short-term ventricular enlargement is related to the degree of ventricular dysfunction and that captopril may improve this process." 10/01/1996 - "When administered (375 micrograms/100 g) to rats with ventricular dysfunction after myocardial infarction in combination with captopril, there was improvement of the resting and stressed cardiac index and LV filling pressure" 02/01/1994 - "Captopril attenuated the development of ventricular dysfunction, neurohumoral activation, ventricular hypertrophy and dilation (endocardial circumference 18 +/- 3 mm) and cardiac fibrosis (3.1 +/- 0.8%, p < 0.05)" 04/01/1990 - "In conclusion, captopril improves asymptomatic ventricular dysfunction and prevents clinical heart failure during the year following myocardial infarction" 12/01/2006 - "data indicate that the addition of low-dose spironolactone to captopril treatment was more effective in preventing the progression of heart hypertrophy and ventricular dysfunction in the SS-16/Mcwi than captopril alone" Order ALL the reference details at left...
10.	CytokinesIBA 03/01/2000 - "These cytokines appear to be activated in response to a remodeling, induction of programmed cell death, neurohormonal activation, and hemodynamics, these agents cause a variety of deleterious effects in the setting of ventricular dysfunction" 01/01/1997 - "In this review, we have included a number of cytokines that may contribute to ventricular dysfunction and/or to the cytoprotective and adaptive changes in the reperfused heart." 05/01/2007 - "In animal models and small-scale clinical trials, anti-TNF therapy showed some promise in treating chronic heart failure, whereas larger, multicenter, randomized, placebo-controlled clinical trials (i.e., RECOVER [Research into Etanercept Cytokine Antagonism in Ventricular Dysfunction] and RENAISSANCE [Randomized Etanercept North American Strategy to Study Antagonism of Cytokines]) failed to show a statistically significant difference in composite clinical function score for anti-TNF therapy versus placebo" 01/01/2004 - "In viral myocarditis and other inflammatory heart diseases, the inflammatory cells and their battery of cytokines may also alter the myocardial MMP-TIMP system and eventually lead to dilation of the heart and ventricular dysfunction" Order ALL the reference details at left...

Therapies and Procedures

1.	Transplants (Transplant) 01/01/1991 - "Twenty patients who had undergone a heterotopic heart transplant were studied prospectively to determine the relationship between rejection and ventricular dysfunction assessed from gated blood-pool studies" 11/01/1995 - "Complications included the need for extracorporeal membrane oxygenation to treat ventricular dysfunction in one patient and graft dehiscence requiring revision of the distal graft in another" 11/01/1989 - "This study was designed to determine if older donor hearts adversely affected cardiac transplant patient prognosis by predisposing them to graft failure from coronary artery disease, ventricular dysfunction, or death" 07/01/2008 - "The following were considered events: death; late rejection; and ventricular dysfunction associated or not with graft vascular disease" 10/01/2007 - "Two groups were made according to the presence of major events after the first year (death, late rejection and ventricular dysfunction associated or not with graft vascular disease): group with events: 13 patients, 37 determinations; group without events: 43 patients, 118 determinations" Order ALL the reference details at left...
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 08/01/2008 - "Ventricular dysfunction was defined as requirement for at least two inotropes or new intra-aortic balloon pump or ventricular assist device support after coronary artery bypass grafting" 01/01/2001 - "Coronary artery bypass grafting is frequently the only therapeutic option, but ventricular dysfunction is generally considered to be a risk factor" 01/01/1998 - "Patients with severe ventricular dysfunction make up a special subset of patients who undergo coronary artery bypass procedures" 01/01/1998 - "Coronary artery bypass grafting in patients with profound ventricular dysfunction." 05/01/1994 - "One of these situations is ventricular dysfunction following coronary artery bypass surgery" Order ALL the reference details at left...
3.	Anesthesia 11/01/1994 - "The use of hypotensive anesthesia is contraindicated in patients with ventricular dysfunction, even though afterload reduction often improves ventricular performance" 02/01/2004 - "Olprinone was very effective for improving ventricular dysfunction; its institution prior to induction of anesthesia made successful anesthetic management possible without resorting to a mechanical assist device like the intra-aortic balloon pump." Order ALL the reference details at left...
4.	Heart Transplantation (Grafting, Heart) 01/01/1998 - "This article analyzes the physiopathology of ventricular dysfunction, present methods to detect the viability of myocardial cells, as well as present indications and results obtained with ventricular revascularization in patients with severe depression of ventricular function as an alternative, currently well established, to heart transplantation." 07/01/1997 - "Aortic valve replacement should be considered even in patients with severe ventricular dysfunction, while the cardiac transplantation should be indicated for patients with a very marked and irreversible depression of myocardial contractility." 05/01/1997 - "It should be proposed in all patients with severe ventricular dysfunction to help define the indications for heart transplantation." 01/01/1997 - "Heart transplantation is an alternative for some patients with severe ventricular dysfunction." 02/01/1992 - "The group as a whole had severe ventricular dysfunction with a median ejection fraction of 17% and a median peak rate of oxygen consumption of 13.7 ml/kg/min. During the follow-up period 23 patients (18%) died and 18 (14%) underwent cardiac transplantation" Order ALL the reference details at left...
5.	Cardiopulmonary Bypass (Heart-Lung Bypass) 11/01/2007 - "Some patients with severe post-cardiotomy ventricular dysfunction are unable to be separated from cardiopulmonary bypass (CPB)" 06/01/2006 - "The use of cardiopulmonary bypass is regarded as a major cause for its occurrence, and it has been postulated that performing coronary surgery without cardiopulmonary bypass might reduce ventricular dysfunction" 09/01/2000 - "Senescent ventricular dysfunction: issues related to cardiopulmonary bypass." 06/01/1999 - "Patients at highest risk for undergoing cardiopulmonary bypass, including those of advanced age and having ventricular dysfunction, are precisely the ones in whom OP-CAB may be the most useful." 02/01/1998 - "Independent perioperative factors that exacerbated risk were cardiopulmonary bypass lasting 3 or mor hours and three measures of ventricular dysfunction" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Ventricular Dysfunction

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 28 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>